Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690881 | 0.86 | ALDH1A1 (0.58) | HCAR3HCAR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12690245 | 0.79 | HCAR3 (0.40) | HCAR3ALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL12690425 | 0.76 | HCAR3 (0.40) | HCAR3KDM4E | |
| SCHEMBL12763797 | 0.74 | HCAR3 (0.46) | HCAR3HCAR2ESR1ALDH1A1KDM4E | |
| SCHEMBL12412536 | 0.74 | HCAR3 (0.54) | HCAR3HCAR2ESR1SMN1; SMN2HRH4 | |
| SCHEMBL19203405 | 0.73 | KDM4E (0.41) | HCAR3HCAR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30658431 | 0.73 | KDM4E (0.41) | HCAR3HCAR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19203407 | 0.73 | KDM4E (0.41) | HCAR3HCAR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12690256 | 0.72 | HCAR3 (0.34) | HCAR3 | |
| SCHEMBL12690364 | 0.72 | HCAR3 (0.47) | HCAR3ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580825-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | HCAR3 211/4885HCAR2 370/4885ESR1 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.